TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04079348

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oasis ECM
Description: The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of Oasis Extracellular Matrix to their donor site wound.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard wound care
Description: The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
Study: NCT02978755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM102
Description: GM102 escalating doses (phase1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM102 escalating doses
Description: GM102 escalating doses combined with paclitaxel and carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM102
Description: GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)
Study: NCT04837300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted Sprint Traininig
Description: The Participants in this group had received plyometrics exercises; double leg jumping, drop jumping, hopping, bounding and hurdling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted Sprint Traininig
Description: The Participants in this group had received plyometrics exercises; double leg jumping, drop jumping, hopping, bounding and hurdling.
Study: NCT00022412

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: doxercalciferol
Description: Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional surgery
Description: Procedure: Prostatectomy for prostate cancer
Study: NCT02344043

Intervention type: DEVICE
Intervention: Near infrared spectroscopy
Description: This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation
Study: NCT03880838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal testimonial
Description: Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal testimonial
Description: Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal testimonial
Description: Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal testimonial
Description: Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal testimonial
Description: Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.
Study: NCT01214603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2090314
Description: Administered intravenously
Study: NCT02739984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection with an automated mini doser

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection with an automated mini doser
Study: NCT00624767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (recombinant human insulin)
Description: Insulin Nasal Spray at doses up to 200 IU.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoLog
Description: NovoLog at doses up to 30 IU
Study: NCT02419638

Intervention type: DRUG
Intervention: Rebif (IFN β-1a subcutaneous three times per week)

Intervention type: DRUG
Intervention: Tecifdera (dimethyl fumarate)
Study: NCT02394132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT01148290

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension free vaginal tape
Description: Small incision sites in the vagina and suprapubically. Bilateral retropubic insertion of the sling by means of needles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bulking agent injection
Description: Three Periurethral injections of Bulkamid ® (Ethicon,Somerville, NJ, USA)
Study: NCT01557595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polarized glasses designed to filter out blue light
Description: Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. They will be instructed to turn off fluorescent lights and only use household lamps for evening activities. They will be instructed not to drive while wearing the glasses. In addition to the oral instructions, they will also be given a written Instruction Sheet. Any oral insomnia agent will be held throughout the study, otherwise they are to follow their usual evening routines. This is an alternative treatment already in use in Dr. Fargason's practice for those patients who don't want to take sleep medications. This research focuses on the effectiveness of this treatment and involves questionnaires to do so.
Study: NCT01616303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks \[21 days\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks \[21 days\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks \[21 days\])
Study: NCT03880838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal testimonial
Description: Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal testimonial
Description: Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.
Study: NCT01616303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks \[21 days\])

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oregovomab
Description: oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).
Study: NCT04366700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery with autograft and collagen membrane
Description: periapical surgery will be done and the defects will be filled with a mixture of autograft and prf and will be covered with a collagen membrane
Study: NCT03880838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal testimonial
Description: Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.
Study: NCT04366700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery with collagen membrane
Description: periapical surgery will be done and the defects will be filled with blood clot and covered with a collagen membrane
Study: NCT03136991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4831
Description: Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3\&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4831
Description: Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3\&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
Study: NCT00265980

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous Placebo
Description: Twice daily injections of saline in the same volume as will be used for leptin injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin
Description: Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.
Study: NCT05988021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.
Study: NCT00780858

Intervention type: DRUG
Intervention: Ganirelix
Description: Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
Study: NCT04381520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion plus antihypertensive drugs
Description: In this arm, patients will administer heat-sensitive moxibustion by themselves or by the help of their family after professional training. Patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive drugs
Description: In this arm, patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
Study: NCT04271514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPT193
Description: Antagonist of the CCR4 chemokine receptor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03684148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery practice
Description: In detail, they were advised to imagine maximal voluntary isometric contractions (MViC). MViC imagery practice was planned in a progressive manner. Thus, it was performed in two sets of 25 repetitions with 2 minutes of inter-sets rest period, for two weeks, and 10 additional repetitions were added on week three and four, respectively. Each MViC repetition was sustained for 5 seconds, followed by 5 seconds of inter-repetition rest periods. Additionally, after every fifth contraction, participants had a 20 seconds of rest. Following 5 days of MI practice, the participants were advised to take a break from MI for two consecutive days. After hospital discharge, the participants in the MIp group were supplied with an audio description of the exercises to be performed.
Study: NCT01371773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repositioning method for left-sided double lumen tubes
Description: When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
Study: NCT03501433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside chloride (Niagen)
Description: 250 mg capsules 2x/day for 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2x/day for 7 days
Study: NCT04271514

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03136991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4831
Description: Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3\&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4831
Description: Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3\&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
Study: NCT03020472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2008-2009 FluMist LAIV (Intranasal)
Description: 2008-2009 FluMist vaccine delivered intranasally
Study: NCT03316859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 MG
Description: Naloxegol 25 mg administered 1 hour pre-operatively

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill administered 1 hour pre-operatively
Study: NCT02489890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced Killer Cells
Description: chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
Study: NCT03404076

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual Energy CT
Description: Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment
Study: NCT03672500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%+Epinephrine 50mc
Description: Local infiltration of the perineum with Bupivacaine 0.5%+Epinephrine 50mc

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection of the perineum
Study: NCT02044471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (using Sphygmomanometer)
Description: Patients in experimental arm will have validated protocol of Remote Ischemic Conditioning (using Sphygmomanometer): 5 minutes with blood pressure cuff inflated at 200 mmHg, then deflated for 5 minutes; repeated for 3 cycles.~Patient in control group will not perform this.
Study: NCT02117193

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol intake
Description: The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol intake
Description: The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sleep deprivation
Description: One night of sleep deprivation or one night of normal sleep.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep deprivation
Description: One night of sleep deprivation or one night of normal sleep.
Study: NCT01003886

Intervention type: DRUG
Intervention: Doxazosin mesylate GITS
Description: Doxazosin mesylate GITS 4mg to 8mg once daily
Study: NCT00534625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zileuton
Description: Single injection of zileuton 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single injection of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zileuton
Description: Single injection of zileuton 300 mg
Study: NCT01976390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 0.75mg twice a day, Orally, starting on day of transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: 5mg, Orally, starting on day of transplant; decreasing to 3mg
Study: NCT00988169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral erlotinib and pulsed doses of oral AT-101
Description: Patients will receive oral erlotinib 100 mg daily and pulsed doses of oral AT-101 given 40 mg twice daily on days 1-3 of a 21-day cycle. If the initial combination of erlotinib and AT-101 is tolerated, dose escalation of erlotinib to 150 mg daily will be allowed at the discretion of the treating investigator at the start of cycle 2. Patients will continue receiving treatment on study until they refuse further therapy, develop evidence of progressive disease, or develop unacceptable toxicity or a medical condition that would, in the judgment of the investigator,
Study: NCT01117961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Behavioral lifestyle intervention targeting diet and physical activity to reduce excessive gestational weight gain
Study: NCT04110795

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT02710461

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixture of grape pomace and pomegranate pomace
Description: Oral Glucose Tolerance Test

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixture of grape pomace and pomegranate pomace
Description: Oral Glucose Tolerance Test right after taking the mixture of grape and pomegranate polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixture of grape pomace and pomegranate pomace
Description: Oral Glucose Tolerance Test ten hours after taking the mixture of grape and pomegranate polyphenols
Study: NCT00928252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV fluorine-18 labeled methylcholine before PET/CT
Description: Intervention at pre-treatment, and at two timepoints post treatment intiation.
Study: NCT00974883

Intervention type: PROCEDURE
Intervention: Ultrasound of temporal and axillary arteries
Description: Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion

Intervention type: PROCEDURE
Intervention: Ultrasound of temporal and axillary arteries
Description: Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion

Intervention type: PROCEDURE
Intervention: Temporal artery biopsy
Description: Biopsy of temporal artery from symptomatic side
Study: NCT01155583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given by subcutaneous injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given by subcutaneous injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study: NCT03640702

Intervention type: OTHER
Intervention: Protocol change
Description: To examine the effect of prolonging the second stage of labor on the rate of cesarean delivery, maternal and neonatal outcomes
Study: NCT02558582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respiratory and exercise therapy
Description: The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respiratory and exercise therapy
Description: The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respiratory and exercise therapy with supplemental oxygen
Description: The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respiratory and exercise therapy with supplemental oxygen
Description: The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights.
Study: NCT02879266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV TV005
Description: Contains 10\^3 plaque-forming units (PFUs) of rDEN1Δ30, 10\^4 PFUs of rDEN2/4Δ30(ME), 10\^3 PFUs of rDEN3Δ30/31-7164, and 10\^3 PFUs of rDEN4Δ30; administered by subcutaneous injection in the deltoid region of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection in the deltoid region of the upper arm
Study: NCT03111056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alc-ERDT
Description: Web-based cognitive behavioral skills-based alcohol intervention that incorporates emotion regulation and distress tolerance skills